Chemomab Therapeutics is merging in an all-stock deal to create a precision medicine leader focused on rheumatoid arthritis. The combined company will be funded through Phase II clinical trial data expected in 2028, positioning it as a significant player in the RA treatment space. The merger consolidates resources and expertise to advance targeted therapies, with the all-stock structure preserving capital while aligning shareholder interests through the critical late-stage development period ahead.
In-Depth:
Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC fillings and other documents provided by Quartr.© 2026 TradingView, Inc.
